Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the last patient was dosed in its Phase 1 single-center clinical study of its oral transmucosal fast-acting high-dose aspirin formulation.
Topline results from the study are anticipated by the middle of third quarter of 2025.
"The successful completion of patient dosing in our Phase 1 trial is a noteworthy accomplishment. We are extremely grateful to the investigator and patients who participated in this study. Achieving this milestone on time and as planned per protocol also demonstrates the operational excellence of our team and clinical partners," said Michael Howe, Chief Executive Officer of Aspire. "We look forward to reporting initial safety and efficacy data in the third quarter, which will provide key insights into our formulation of high-dose aspirin and its potential as a fast-acting treatment option for suspected acute myocardial infarction. Following the receipt of the topline results, we plan to continue discussions with the FDA to ensure our path forward is well-aligned with regulatory expectations."
Howe added, "We are eager to integrate the insights from this trial into our comprehensive development plan. We believe these trial results will also play a key role in our strategy to pursue potential partnership opportunities."
Phase 1 Study Design
The Phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the administration of our sublingual dose of 162.5 mg aspirin powder with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post-dose). The trial also measures Arachidonic acid (AA)-induced platelet aggregation over 8 hours after dosing and Serum thromboxane B2 (TxB2) over 8 hours after dosing, both of which are valuable for documenting Aspire's sublingual high-dose aspirin's rapid impact on cardiac events.
Following completion of this trial, Aspire plans to submit a section 505(b)(2) NDA seeking approval to market the high-dose aspirin product.
About the Aspire Targeted Oral Delivery Platform
Aspire's technology delivers a soluble, fast-acting granular or powder formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of drugs and other substances. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities.
About Aspire Biopharma, Inc.
Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IRKevin McGrath+1-646-418-7002kevin@tradigitalir.com
SOURCE: Aspire Biopharma Holdings, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Microsoft Stock Is Getting Expensive. Should Investors Be Worried or Buy Anyway?
Key Points Microsoft continues to raise the bar despite difficult comps. An expensive valuation will pressure Microsoft to keep delivering exceptional results. Microsoft stock may be due for a pause, but it is still a long-term buy. 10 stocks we like better than Microsoft › Microsoft (NASDAQ: MSFT) has been a standout growth stock in 2025, adding more than $830 billion in market cap from the start of the year through the end of July. But some investors may be concerned that Microsoft is running up too far too fast, setting the stage for a pullback due to valuation concerns. Here's why Microsoft's valuation is pretty much the only thing holding it back from being a screaming buy, and why the company can grow into its valuation over time. Microsoft and the effectiveness of consistent compounding Microsoft is a textbook example of the power of compounding solid growth over an extended period. Over the last decade, cloud and artificial intelligence (AI) have been the two biggest drivers of Microsoft's sales and earnings growth. An honorable mention is the vertical integration of Microsoft's gaming business (under its More Personal Computing segment) through Xbox, content services, and the acquisition of Activision Blizzard. Over the last decade, Microsoft's revenue more than tripled, and its net income is up more than sixfold. The company generated more net income in fiscal 2025 than revenue in fiscal 2017 -- illustrating the impact of high-margin growth on Microsoft's bottom line. Fiscal Year 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Revenue (billions) $85.3 $90 $110.4 $125.8 $143 $168.1 $198.3 $211.9 $245.1 $281.7 Net income (billions) $16.8 $21.2 $16.6 $39.2 $44.3 $69.9 $72.7 $72.4 $88.1 $101.8 Net profit margin 19.7% 23.6% 15% 31.2% 31% 41.6% 36.7% 34.2% 35.9% 36.1% Data source: Microsoft. Microsoft has been consistently growing revenue, but net income is growing even faster. In fiscal 2025, Microsoft raked in around $0.36 of every dollar in revenue into bottom-line profit. That's profit net of all expenses -- including taxes. That's an incredible achievement, especially considering how much Microsoft's expenses have gone up in recent years. Microsoft is relatively expensive Microsoft's rapid growth in the second half of the 2010s was driven by Azure and the widespread adoption of cloud computing. But everything has been clicking for Microsoft over the last three years. The company grew revenue by roughly 15% in fiscal 2023, 2024, and now 2025 -- surpassing $100 billion net income for a fiscal year for the first time in company history. Microsoft's stock price responded to these impeccable results by compounding several-fold. And for a while, the valuation was arguably too cheap to ignore. But now, Microsoft is being valued for what it has become, which is an ultra-high-margin, diversified business growing revenue in the mid-teens rather than the high single digits or low teens of years past. This valuation expansion has pushed Microsoft's price-to-earnings (P/E) ratio close to 40 -- whereas its 10-year median P/E is 33.1. Growing into its valuation Microsoft has never been a better company, but it has also become a much more expensive stock. Over time, Microsoft has justified its high valuation by consistently growing revenue and earnings. And now more than ever there's reason to believe that can continue. Anything can happen in the stock market in the short term. But when it comes to long-term investing, buying ultra-high-quality companies at premium prices is usually worth it. As an example, if Microsoft keeps growing earnings at 15% per year, earnings will double in five years. If the stock price did nothing over that period, the P/E would be cut in half, down to around 20. If the stock price gained another 50%, the P/E would fall to 30 -- a discount to Microsoft's historical average. Justifying a premium price Microsoft won't look expensive if it keeps up this pace of earnings growth. The power of compound returns is why the market is willing to pay a high price for Microsoft today. As an individual investor, you have the luxury of choosing whether to agree with a prevailing sentiment. Right now, the sentiment is optimistic on Microsoft. So to buy the stock requires a long-term time horizon and the conviction that the optimism is grounded in logic rather than greed. But if you believe that a lot of Microsoft's growth is due to a surge in AI adoption that will cool off as the technology becomes widespread, then it's perfectly all right to take a wait-and-see approach to the stock. Do the experts think Microsoft is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Microsoft make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Microsoft Stock Is Getting Expensive. Should Investors Be Worried or Buy Anyway? was originally published by The Motley Fool
Yahoo
23 minutes ago
- Yahoo
5 No-Brainer Growth Stocks to Buy Right Now
Key Points Nvidia and Alphabet are two tech titans benefiting from AI. GitLab has a strong growth opportunity in front of it as AI accelerates software development. Dutch Bros and e.l.f. are two of the most exciting growth stories in the consumer space. 10 stocks we like better than Nvidia › Growth stocks have been leading the market higher for several years, and right now there are no signs of this trend slowing down. While growth stocks can be found in any sector, two of the most common places to find them are in technology and the consumer spaces. Let's look at five no-brainer growth stocks to buy now. Nvidia Nvidia (NASDAQ: NVDA) is the clear-cut artificial intelligence (AI) leader, and it's not even close. The company captured an absurd 92% share of the graphics processing unit (GPU) market in the first quarter, and yet it's still in full-on growth mode. Despite topping a $4 trillion market cap, Nvidia continues to expand rapidly, driven by demand for its data center chips. Its real moat, though, is its CUDA software platform. Nvidia got CUDA into the hands of researchers and academics way before AI went mainstream, and now it has a dominant developer ecosystem built on its tools and libraries. If you listen to any of the commentary from cloud computing companies, AI infrastructure spending is only increasing. Meanwhile, the company just got the green light to resume H20 chip sales in China. While the Chinese government wants Nvidia to provide security proofs, demand is already reported to be robust. At the same time, its automotive segment is well positioned for a robotaxi future. Given the growth opportunities still in front of Nvidia, it looks like a no-brainer long-term winner. Alphabet Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) continues to be wildly underappreciated. With Alphabet trading at just 19 times forward earnings with a forward price/earnings-to-growth ratio (PEG) of 0.8, the market is treating it like its best days are behind it. However, nothing could be further from the truth. Google Search isn't going anywhere -- it's evolving -- and Alphabet is steering that evolution with AI Overviews, its Gemini model, and multimodal search tools like Circle to Search and Google Lens. In Q2, its search revenue accelerated to 12% growth, and over 2 billion people are already using AI Overviews. Its cloud computing unit, Google Cloud, is also firing on all cylinders, with revenue up 32% and segment profit more than doubling last quarter. AI is the big driver, as customers create AI models and tools through its Vertex platform and then deploy them on its infrastructure. Its custom-built Tensor Processing Units (TPUs), meanwhile, have been designed specifically to optimize AI workloads within Google Cloud's TensorFlow framework, leading to increased efficiency and a cost advantage. At the same time, YouTube is holding its own with ad revenue up 13% in Q2, and its Waymo robotaxi is expanding into more cities. All in all, Alphabet is a great mix of leading and emerging businesses. GitLab GitLab (NASDAQ: GTLB) is no longer just a code repository -- it's turning into the software development backbone for the AI era. With GitLab 18, the company introduced more than 30 new features, including its Duo Agent, which enables AI-driven testing, deployment, security, and monitoring. That's important, since only about 20% of a developer's time is spent writing code. GitLab is now helping with the drudgery of the other 80%, helping developers become more efficient. The company has already been a strong revenue grower, consistently growing its revenue by 25% or more since its stock debuted in 2021. AI, meanwhile, has only accelerated software development. While some fear that AI will lead to fewer coders, given the value of its platform, there is a good chance the company could eventually shift from a seat-based model to consumption-based pricing, giving the increasing value proposition of its platform In a world where AI is changing how software gets built, GitLab's end-to-end platform is becoming vitally important. That puts it in a very strong spot going forward. Dutch Bros Dutch Bros (NYSE: BROS) might not be a household name outside the western U.S., but it's one of the most promising restaurant growth stories out there. The company just passed 1,000 locations and has a clear path to achieve its goal of 2,029 locations by 2029. Its model is capital-light, with a small drive-thru-only footprint that makes expansion quick and cost effective. Its long-term goal, meanwhile, is to have around 7,000 locations nationwide. But there's more to the Dutch Bros story than just expansion. Its same-store sales have been strong, and the company is still in the early stages of rolling out mobile ordering, which should speed up throughput and help drive peak-hour volumes. It's also testing hot breakfast items, which could unlock a major new revenue stream. Dutch Bros has been getting less than 2% of its sales from food items, compared to nearly 20% for Starbucks, so this is a huge opportunity. Meanwhile, the brand resonates with younger consumers; it doesn't spend heavily on marketing, its prices are generally cheaper than rival Starbucks', and its overhead is pretty low given its drive-thru model. All in all, Dutch Bros is one of the best growth stories in the restaurant space. e.l.f. Beauty e.l.f. Beauty (NYSE: ELF) already disrupted the mass cosmetics market, and now it's looking to do the same in prestige beauty with its Rhode acquisition. Rhode is already generating over $200 million in sales with no retail footprint, but that's about to change. Rhode is rolling out at Sephora in the fall, and it will benefit from e.l.f.'s strong retail relationships in the future. Rhode founder Hailey Bieber will stay on to help run the creative side and brings a lot of clout to the brand. Meanwhile, e.l.f.'s influencer strategy has helped it take a huge share in the mass cosmetics market over the past few years, so expect this marketing network to help drive growth at Rhode as well. In addition, with Rhode having only a modest product lineup, an increased product assortment is also likely in the cards. e.l.f. has a huge runway to grow the already viral Rhode brand -- from increasing distribution, to adding marketing, to expanding the number of Rhode SKUs it sells. After e.l.f. hit a recent bump in the road in terms of growth, expect Rhode to become a huge growth driver for the company in the coming years. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has positions in Alphabet, GitLab, and e.l.f. Beauty. The Motley Fool has positions in and recommends Alphabet, GitLab, Nvidia, Starbucks, and e.l.f. Beauty. The Motley Fool recommends Dutch Bros. The Motley Fool has a disclosure policy. 5 No-Brainer Growth Stocks to Buy Right Now was originally published by The Motley Fool
Yahoo
42 minutes ago
- Yahoo
Why Opendoor (OPEN) Shares Are Sliding Today
What Happened? Shares of technology real estate company Opendoor (NASDAQ:OPEN) fell 22.7% in the afternoon session after the company issued a weak financial forecast for the upcoming third quarter, overshadowing its recent earnings report. The online real estate platform projected third-quarter revenue between $800 million and $875 million, a steep decline from the previous year and well below market expectations. Opendoor also guided for a return to a loss on an adjusted earnings basis. This gloomy forecast soured investor sentiment despite the company reporting better-than-expected revenue of about $1.6 billion for its second quarter. The poor outlook stemmed from a difficult home-buying environment, as high interest rates discouraged potential buyers and decreased sales. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Opendoor? Access our full analysis report here, it's free. What Is The Market Telling Us Opendoor's shares are extremely volatile and have had 86 moves greater than 5% over the last year. But moves this big are rare even for Opendoor and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 9.5% on the news that the company announced it had regained compliance with Nasdaq's minimum bid price requirement, leading to the cancellation of a vote on a reverse stock split. The news removed the immediate threat of the stock's delisting from the exchange. The company consequently canceled a special shareholder meeting scheduled to vote on the reverse stock split, a move often viewed negatively by investors. This positive development occurred ahead of the company's second-quarter earnings report, which loomed as a major test following the stock's recent surge, fueled in part by its popularity among traders. Opendoor is up 25.2% since the beginning of the year, but at $1.99 per share, it is still trading 38% below its 52-week high of $3.21 from July 2025. Investors who bought $1,000 worth of Opendoor's shares 5 years ago would now be looking at an investment worth $180.34. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
